Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8942331rdf:typepubmed:Citationlld:pubmed
pubmed-article:8942331lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:8942331lifeskim:mentionsumls-concept:C0010055lld:lifeskim
pubmed-article:8942331lifeskim:mentionsumls-concept:C0022616lld:lifeskim
pubmed-article:8942331lifeskim:mentionsumls-concept:C0376618lld:lifeskim
pubmed-article:8942331lifeskim:mentionsumls-concept:C0342952lld:lifeskim
pubmed-article:8942331lifeskim:mentionsumls-concept:C0032790lld:lifeskim
pubmed-article:8942331pubmed:issue4lld:pubmed
pubmed-article:8942331pubmed:dateCreated1996-12-30lld:pubmed
pubmed-article:8942331pubmed:abstractTextIn a randomized, double-blind clinical study in 29 patients undergoing elective coronary artery surgery, we assessed the role of ketanserin, an inhibitor of serotonin-induced vasoconstriction and weak alpha 1 sympathetic blocker, in reducing endotoxaemia and postoperative hypermetabolism. Male patients without major organ dysfunction were allocated randomly to receive either ketanserin or placebo. Hypermetabolism was defined as an increase in oxygen consumption in the early postoperative hours (delta Vo2). Circulating endotoxin (P = 0.04) and postoperative delta Vo2 (P = 0.03) were lower in the ketanserin patients. Endotoxaemia was associated also with low vascular filling. From these preliminary results we conclude that treatment with ketanserin during cardiac surgery may reduce but not abolish endotoxaemia and postoperative hypermetabolism.lld:pubmed
pubmed-article:8942331pubmed:languageenglld:pubmed
pubmed-article:8942331pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8942331pubmed:citationSubsetIMlld:pubmed
pubmed-article:8942331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8942331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8942331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8942331pubmed:statusMEDLINElld:pubmed
pubmed-article:8942331pubmed:monthOctlld:pubmed
pubmed-article:8942331pubmed:issn0007-0912lld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:WildevuurC...lld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:SturmCClld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:StoutenbeekC...lld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:EijsmanLLlld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:Oudemans-van...lld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:ZandstraD FDFlld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:JansenP GPGlld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:VelthuisHHlld:pubmed
pubmed-article:8942331pubmed:authorpubmed-author:DeventerS JSJlld:pubmed
pubmed-article:8942331pubmed:issnTypePrintlld:pubmed
pubmed-article:8942331pubmed:volume77lld:pubmed
pubmed-article:8942331pubmed:ownerNLMlld:pubmed
pubmed-article:8942331pubmed:authorsCompleteYlld:pubmed
pubmed-article:8942331pubmed:pagination473-9lld:pubmed
pubmed-article:8942331pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:meshHeadingpubmed-meshheading:8942331-...lld:pubmed
pubmed-article:8942331pubmed:year1996lld:pubmed
pubmed-article:8942331pubmed:articleTitleEndotoxaemia and postoperative hypermetabolism in coronary artery bypass surgery: the role of ketanserin.lld:pubmed
pubmed-article:8942331pubmed:affiliationDepartment of Intensive Care, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.lld:pubmed
pubmed-article:8942331pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8942331pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8942331pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:8942331pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed